Related Experiment Videos
Update on antiplatelet therapy for stroke prevention
1Department of Neurology and Public Health Epidemiology, Sergievsky Center, Neurological Institute, College of Physicians and Surgeons of Columbia University, New York Presbyterian Hospital, New York 10032, USA. rls1@columbia.edu
Insights
For patients at risk of recurrent stroke, the combination of aspirin and extended-release dipyridamole offers effective prevention. This antiplatelet therapy is recommended as a first-line treatment due to its proven efficacy and safety profile.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Pharmacology
Background:
- Ischemic stroke leads to high mortality and disability rates, necessitating effective preventive strategies.
- Patients with transient ischemic attack (TIA) or stroke face a high risk of recurrence.
- Risk-factor management is crucial for individuals with cerebrovascular disease.
Purpose of the Study:
- To evaluate the efficacy and safety of antiplatelet therapies for secondary stroke prevention.
- To assess the combination of low-dose aspirin plus extended-release dipyridamole compared to monotherapy.
Main Methods:
- The study involved analyzing data from the second European Stroke Prevention Study.
- Participants included patients who had experienced a transient ischemic attack or stroke.
- Treatment groups received aspirin, ticlopidine, clopidogrel, or a combination of aspirin and extended-release dipyridamole.
Main Results:
- The combination of low-dose aspirin plus extended-release dipyridamole was significantly more effective than aspirin alone in preventing recurrent stroke.
- This combination demonstrated a favorable safety profile with few treatment-related adverse effects.
- The combination therapy proved superior to monotherapy in the studied patient population.
Conclusions:
- Low-dose aspirin plus extended-release dipyridamole is a safe and effective first-line treatment for stroke prevention in high-risk patients.
- This combination therapy represents a significant advancement in secondary stroke prevention strategies.
- The findings support current recommendations for using this combination after TIA or stroke.
Abstract:
The high rates of mortality and long-term disability associated with ischemic stroke, coupled with its prevalence, necessitate good, long-term preventive strategies. Risk-factor management is effective for individuals with preclinical and clinical cerebrovascular disease. Patients suffering from a transient ischemic attack or stroke are particularly vulnerable to subsequent stroke. Most of these individuals are candidates for antiplatelet treatment to prevent a recurrence. Available antiplatelet therapies include aspirin, ticlopidine, and clopidogrel. The combination of low-dose aspirin plus extended-release dipyridamole has been shown to offer safe, effective antiplatelet therapy for appropriate patients. In the second European Stroke Prevention Study, the combination was found to be significantly more effective than either drug alone, at the cost of relatively few treatment-related adverse effects. This combination is currently recommended as one of the first-line treatments for stroke prevention after first transient ischemic attack or stroke.